Less Than 4 Lymph Nodes Harvested Indicates More Tumor Deposits and Worst Survival in Locally Advanced Rectal Cancer with Neoadjuvant Chemoradiotherapy
Y. Wang,L. Yang,M. Zhou,J. Zhang,L. Shen,J. Wan,J. Zhu,Z. Zhang
DOI: https://doi.org/10.1016/j.ijrobp.2019.06.2066
2019-01-01
Abstract:Several studies demonstrated a decrease in lymph node yield (LNY) in locally advanced rectal cancer (LARC) with neoadjuvant chemoradiotherapy (neo-CRT), which was related to good tumor response. However, some studies denied this conclusion. This study aimed to investigate factors related to LNY and its prognostic value in those patients. Between 2006 and 2015, 495 LARC patients following neo-CRT and surgery were retrospectively analyzed. Clinicopathological features, overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and distant metastasis free survival (DMFS) were recorded. The patients were separated into several groups: LNY (0-4) group, LNY (5-8) group, LNY (9-12) group, LNY (13-16) group, LNY (17-20) group and LNY (>20) group. The chi-square test was performed to compare clinicopathological differences by LNY groups. Univariate and multivariate survival analysis were performed using the Kaplan-Meier method and the Cox proportional hazards regression in all patients, lymph node negative patients and lymph node positive patients. Of the 495 patients, the cases were found 62 (12.5%), 132 (26.7%), 149 (30.1%), 97 (19.6%), 34(6.9%), 21(4.2%) in LNY (1-4) group, LNY (5-8) group, LNY (9-12) group, LNY (13-16) group, LNY (17-20) group and LNY (>20) group. There were no clinicopathological differences by LNY groups, including age, gender, distance from anus, surgical procedures, tumor grade, cTNM staging, ypTNM staging and tumor regression grade (TRG) (all P＞0.05). LNY<12 was significantly associated with smaller tumors (maximum diameter <3cm), especially in LNY≤4 group (56.5%, 52.3%, 53.0% in LNY≤12 groups vs. 45.4%, 35.3%, 19.0% in LNY>12 groups, P=0.002). In addition, tumor deposits are more significantly found in LYN≤4 group (32.3% in LNY≤4 group vs. 18.2%, 16.8%, 10.3%, 17.6%, 14.3% in LNY>4 groups, P=0.024). In LN-negative patients, LNY≤4 group was only related to more tumor deposits (P=0.011). However, in LN-positive patients, LNY≤4 group was significantly related to older patients (>50 years old, P=0.023), smaller tumors (maximum diameter <3cm, P=0.003), tumor deposit (P=0.040) and neural invasion (P=0.054). Kaplan-Meier survival analysis showed that LYN≤4 group had worst OS (P=0.016), DFS (P=0.001), and DMFS (P=0.003) compared with other groups in all LARC patients, but not LRFS (P=0.059). In LN-negative patients, LYN≤4 group had worst OS (P=0.006), DFS (P=0.001), LRFS (P=0.030) and DMFS (P=0.005). However, in LN-positive patients, there was a tendency to have worst OS, DFS, and DMFS in LYN≤4 group, but not reaching the statistical significance. In multivariate survival analysis, LNY≤4 was an independent poor prognostic factor of OS, DFS, and DMFS in all patients and LN-negative patients. Less than 4 lymph nodes harvested in the surgical specimen indicate more tumor deposits and worst survival in LARC patients with neo-CRT.